Skip to content
Back to Investors
NA

New Anglia Capital

Government

New Anglia Capital is a co-investment fund backed by the New Anglia Local Enterprise Partnership and Anglia Capital Group to provide match funding for early-stage and high-growth ventures.


Recent investments

Seed
£75.0K

The Norfolk-based start-up raised the capital from Anglia Capital Group and New Anglia Capital to support its environmental monitoring technology.

"When WATR pitched to our members they were immediately impressed by the mission to improve water conditions around the world. Businesses with a focus on sustainability are increasingly seeing success in gaining early-stage funding as more of our members seek to invest in companies which are having a positive impact on the environment. We wish WATR every success for the future and look forward to seeing them go from strength to strength"
— Hannah Smith, Managing Director
Seed
£360K

The Norwich-based vegan pizza company raised the funds from Anglia Capital Group and New Anglia Capital.

"Our members loved the story behind One Planet Pizza. Veganism is on the rise and anything we can do to reduce our carbon footprint is surely a good thing, especially if it tastes good too!"
— Hannah Smith, Managing Director
Other
£615K

The company surpassed its initial £530k target with backing from angels and institutional funds.

"To develop this expertise Spark requires a collaborative venture with suitably qualified experts to add to its engineering team. Our partnership will accelerate our speed to market and deliver leading functionality in an affordable way, helping us increase market growth and technology independence. Thank you for your support during the process."
— Justin Ott, CEO
Seed
£1.3M

The Norwich-based diagnostics firm secured £1.3m immediately with up to £2m committed for 2021 from a syndicate of angel and local enterprise investors.

"There’s a vast, global potential in the application of our unique technology. We are using it to tackle Covid now, but it will also produce better vaccines and new diagnostic and therapeutic products in the future. The investment we have secured will enable us to attract new talent to the team at Iceni and maximise the significant opportunities we have in our pipeline."
— Rob Field, Co-founder